Literature DB >> 10537134

Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development.

W Ruan1, D L Kleinberg.   

Abstract

Previous studies from this laboratory have emphasized the essential role of GH in pubertal mammary development and shown that insulin-like growth factor I (IGF-I) was capable of substituting for GH in this process in rats and mice. The present study shows that, even when GH is present, no mammary development is possible unless IGF-I is present. IGF-I(-/-) null female animals were found to have significantly less mammary development than age matched wild-type controls (P <0.006) using several endpoints including the number of terminal end buds or TEBs (1.3 vs. 7.3), percent of the fat pad occupied by glandular elements (6.5 vs. 100), and number of ducts (15 vs. too numerous to count). That the deficiency in mammary gland development was related to the absence of IGF-I was underscored by the observation that des (1-3) IGF-I administration to IGF-I(-/-) null animals for 5 days caused significant mammary gland development as measured by TEB formation and branching of ducts. The number of TEBs rose from a mean of 1.3 in controls to 20.5 without added E2 (P < 0.009), and from 1.7 to 21 when des (1-3) IGF-I was given together with E2 (P < 0.006). The number of ducts increased significantly from a mean of 12 to 27 in response to IGF-I and E2, and from 15 to 24.5 with IGF-I alone. In contrast, administration of human GH with E2 had no stimulatory effect on mammary development in these animals, indicating that the full effect of GH in this process is mediated by IGF-I. To determine whether IGF-I was also responsible for further ductal morphogenesis, we administered des (1-3) IGF-I + E2 to the knockout animals for 14 days and compared the effects of this combination of hormones on mammary development with those observed after 5 days. We found that there was a significant increase from 5 to 14 days in the number of TEBs (mean: 21 vs. 41) and the area of the mammary fat pad occupied by glands (mean: 10 vs. 20%). There was elongation and thickening of the ducts which accounted for the increased area that was occupied by ductal structures. There was no significant increase in the number of ducts. However, there was the appearance of a large number of buds along the length of the ductal structures, suggesting the beginning of side branching. These results suggest that IGF-I, when given along with E2, is responsible for ductal morphogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10537134     DOI: 10.1210/endo.140.11.7095

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  75 in total

1.  Growth hormone stimulates remnant small bowel epithelial cell proliferation.

Authors:  Xin Zhou; Ning Li; Jie-Shou Li
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

2.  Elevated circulating IGF-I promotes mammary gland development and proliferation.

Authors:  Dara Cannata; Danielle Lann; Yingjie Wu; Sebastien Elis; Hui Sun; Shoshana Yakar; Deborah A Lazzarino; Teresa L Wood; Derek Leroith
Journal:  Endocrinology       Date:  2010-10-06       Impact factor: 4.736

Review 3.  Growth factor regulation of cell cycle progression in mammary epithelial cells.

Authors:  Malinda A Stull; Anne M Rowzee; Aimee V Loladze; Teresa L Wood
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

Review 4.  Synthetic adipose tissue models for studying mammary gland development and breast tissue engineering.

Authors:  Xiuli Wang; Michaela R Reagan; David L Kaplan
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-09-12       Impact factor: 2.673

5.  Mammary ductal growth is impaired in mice lacking leptin-dependent signal transducer and activator of transcription 3 signaling.

Authors:  Stephanie R Thorn; Sarah L Giesy; Martin G Myers; Yves R Boisclair
Journal:  Endocrinology       Date:  2010-05-25       Impact factor: 4.736

6.  Altered mammary gland development in the p53+/m mouse, a model of accelerated aging.

Authors:  Catherine E Gatza; Melissa Dumble; Frances Kittrell; David G Edwards; Robert K Dearth; Adrian V Lee; Jianming Xu; Daniel Medina; Lawrence A Donehower
Journal:  Dev Biol       Date:  2007-10-12       Impact factor: 3.582

Review 7.  Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.

Authors:  David L Kleinberg; Teresa L Wood; Priscilla A Furth; Adrian V Lee
Journal:  Endocr Rev       Date:  2008-12-15       Impact factor: 19.871

8.  Prepubertal exposure to arsenic(III) suppresses circulating insulin-like growth factor-1 (IGF-1) delaying sexual maturation in female rats.

Authors:  Michael P Reilly; James C Saca; Alina Hamilton; Rene F Solano; Jesse R Rivera; Wendy Whitehouse-Innis; Jason G Parsons; Robert K Dearth
Journal:  Reprod Toxicol       Date:  2013-09-30       Impact factor: 3.143

9.  CrkII transgene induces atypical mammary gland development and tumorigenesis.

Authors:  Kelly E Fathers; Sonia Rodrigues; Dongmei Zuo; Indrani Vasudeva Murthy; Michael Hallett; Robert Cardiff; Morag Park
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

10.  A Convenient Method for Evaluating Epithelial Cell Proliferation in the Whole Mammary Glands of Female Mice.

Authors:  Grace E Berryhill; Ingrid Brust-Mascher; Jill H Huynh; Thomas R Famula; Colin Reardon; Russell C Hovey
Journal:  Endocrinology       Date:  2016-08-29       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.